Bintie Biotechnology

What Bintie Biotechnology does

Shanghai Bintie Biotechnology Co., Ltd. (上海镔铁生物科技有限责任公司) is a privately held, clinical-stage biotech founded in 2021 and headquartered in Shanghai's Pudong New District. The company develops TCR-T cell therapies and bispecific T cell engagers that target oncogenic driver mutations — primarily KRAS mutations, with an emphasis on KRAS G12V — in solid tumors. Its lead clinical asset, IX001 TCR-T, targets advanced pancreatic cancer and colorectal cancer and entered Phase I clinical trials in March 2025, with the first patient reported to have achieved a partial response within 28 days (September 2025).

The company's technology foundation rests on four proprietary platforms. TAILOR is a bespoke, high-throughput TCR discovery platform for identifying receptors against oncogenic driver mutations. TUNE applies synthetic biology and gene editing to engineer T cells that persist in the immunosuppressive tumor microenvironment. THRIVE is the manufacturing platform producing cell products with optimized phenotypes. TETHER extends beyond cell therapy by using yeast display affinity maturation to produce half-life-extended bispecific T cell engagers with anti-CD3 binding. Beyond the autologous IX001 TCR-T, the pipeline includes TCR-NK (allogeneic) and TCR-ICE (off-the-shelf TCR fusion protein) products that leverage the same proprietary KRAS-targeting TCR sequences, covering both personalized and universal cell therapy modalities.

Bintie is pre-revenue. Its commercial model will eventually rest on out-licensing or direct commercialization of cell therapy products to hospitals and specialty cancer centers, with pricing to be determined upon regulatory approval. Current go-to-market activity is sales-led through hospital-based investigator-initiated trials (IITs) and the newly opened registered IND trial, with direct patient recruitment via the corporate website. The company has raised over CNY 100 million in a Series A round (October 2023) led by Guotou Chuangye (SDIC Venture Capital), with participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. Founder and Project Chief Scientist Hong-Ming Hu, Ph.D., has international credentials in tumor immunotherapy developed in the United States, and the company has received the Shanghai "Specialized, Refined, and Innovative SME" designation and National Key R&D Program selection.

Name

Bintie Biotechnology

Legal name

Shanghai Bintie Biotechnology Co., Ltd. (上海镔铁生物科技有限责任公司)

Website

https://immuxell.cn

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Bintie Biotechnology (Shanghai Bintie Biotechnology Co., Ltd.) is a clinical-stage biotech developing TCR-T cell therapies and bispecific T cell engagers targeting KRAS mutations in solid tumors, with lead product IX001 currently in Phase I trials for advanced pancreatic and colorectal cancer.

Ownership category

akta.pro rank

Product category

Cell Therapy Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industry

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• TCR-T cell therapy
• Solid tumor immunotherapy
• KRAS mutation targeting
• Bispecific T cell engagers
• Cancer cell therapy products

Headquarters

HQ city

Pudong

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. TCR-T Cell Therapy Products: As a clinical-stage biotech, Bintie Biotechnology's primary revenue model is developing and commercializing novel TCR-T cell therapy products targeting KRAS mutations for solid tumors. The company is advancing through clinical trials with lead product IX001 TCR-T for pancreatic and colorectal cancer.
2. TCR-NK (Allogeneic Cell Therapy): Off-the-shelf allogeneic NK cell therapy products incorporating proprietary KRAS-targeting TCR sequences, offering potential faster time-to-treatment than autologous approaches.
3. TCR-ICE (TCR Fusion Protein): Off-the-shelf TCR fusion protein (bispecific antibody format) that can be mass-produced and supplied to hospitals without cell collection and reinfusion procedures, representing a universal product opportunity.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Bintie Biotechnology is a clinical-stage biotech company developing novel TCR-T cell therapies and bispecific T cell engagers that target oncogenic driver mutations, particularly KRAS mutations (G12V), for the treatment of solid tumors. Its lead product IX001 TCR-T is in Phase I clinical trials for advanced pancreatic cancer and colorectal cancer, with additional pipeline candidates TCR-ICE (off-the-shelf TCR fusion protein) and TCR-NK (allogeneic NK cell therapy) built on four proprietary technology platforms.

Product overview

Bintie Biotechnology (镔铁生物) is a clinical-stage biotech company developing a portfolio of immunocyte preparations targeting solid tumors, with a focus on TCR-T cell therapies. The core product IX001 TCR-T targets KRAS mutations (G12V) for pancreatic and colorectal cancers. The pipeline includes TCR-ICE (off-the-shelf TCR fusion protein) and TCR-NK (allogeneic NK cell therapy). The technology portfolio comprises four proprietary platforms: TAILOR (TCR discovery), TUNE (T cell engineering), THRIVE (manufacturing), and TETHER (bispecific T cell engagers). The company integrates personalized and universal cell therapy approaches, leveraging these platforms to target shared cancer driver gene mutations and tumor neoantigens.

Differentiator

Problem solved

Functional benefit

Products and services

• IX001 TCR-T Cell Therapy A TCR-T cell therapy product targeting KRAS mutations (particularly KRAS G12V), developed for the treatment of advanced pancreatic cancer and colorectal cancer. The company's most advanced product, having completed TCR screening, in vitro functional identification, in vivo efficacy experiments, and investigator-initiated clinical trials, with first patient achieving partial response in 28 days.
• TCR-ICE (TCR Fusion Protein) An off-the-shelf TCR fusion protein product combining proprietary KRAS mutation TCR sequences with anti-CD3 scFv. Unlike cell therapy, it does not require blood collection and reinfusion procedures, and can be mass-produced for hospital use.
• TCR-NK An allogeneic cell therapy product that introduces proprietary KRAS mutation TCR sequences into NK cells. NK cells have natural tumor-killing ability and can be used in allogeneic settings, offering advantages over conventional autologous or allogeneic T cell therapies with faster time-to-treatment.

Quantifiable outcome

• First patient achieved partial response in 28 days in Phase I clinical trial for IX001 TCR-T in late-stage pancreatic cancer
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Adaptimmune Therapeutics: Clinical-stage TCR-T cell therapy company with approved product Tecelra for synovial sarcoma and a pipeline targeting MAGE-A4 and other solid-tumor antigens. Most direct global comparable to Bintie's TCR-T autologous solid-tumor strategy, with deeper clinical maturity but similar modality focus.
• Immatics: Clinical-stage TCR-T and TCR-bispecific company with multiple solid-tumor programs targeting tumor-specific peptides. Comparable on modality (TCR-T and TCR bispecifics), solid-tumor focus, and platform-based pipeline expansion strategy.
• Affini-T Therapeutics: Clinical-stage biotech developing TCR-T cell therapies targeting oncogenic driver mutations, including KRAS — the same core target and modality strategy as Bintie. Closest mechanistic and strategic peer, focused on KRAS G12V and other oncogenic drivers with TCR-T and bispecific platforms.
• TCR Therapeutics (TCR-T programs): Pioneer in TCR-T cell therapy for solid tumors (gavocabtagene autoleucel for mesothelin). Direct comparable on autologous TCR-T modality targeting solid tumors, though currently focused on a different antigen target.

Regional players

• CARsgen Therapeutics: China-based clinical-stage cell therapy company with autologous CAR-T programs for solid tumors (e.g., Claudin18.2 CAR-T for gastric cancer). Comparable as a China clinical-stage cell therapy peer pursuing difficult solid-tumor indications with engineered T cells.
• Gracell Biotechnologies: China-based allogeneic CAR-T developer (now part of AstraZeneca) advancing FasT-CAR and TruUCAR platforms. Comparable to Bintie on the China cell therapy ecosystem and on the allogeneic/off-the-shelf angle similar to TCR-NK.
• JW Therapeutics (Legend Biotech subsidiary): China-based cell therapy company commercializing CAR-T products (Carteyva) and developing next-gen cell therapies including allogeneic platforms. Comparable to Bintie as a China-domestic cell therapy peer operating in the same regulatory and clinical ecosystem.

Broad incumbents

• Amgen (Lumakras/sotorasib and KRAS pipeline): Global biopharma with the first FDA-approved KRAS G12C inhibitor (Lumakras/sotorasib) and a broad KRAS franchise. Relevant comparable on KRAS target competition; though small-molecule modality differs, it sets the efficacy benchmark TCR-T programs must beat or combine with.
• Moderna (KRAS mRNA-5671 / mRNA-4157 programs): Large biotech developing mRNA-based cancer vaccines including KRAS-targeted programs in collaboration with Merck. Indirect comparable to Bintie's TCR-T KRAS strategy on shared KRAS target and solid-tumor focus, though using a different modality.

Emerging players

• Allogene Therapeutics: Clinical-stage allogeneic (off-the-shelf) CAR-T company advancing multiple solid-tumor and hematology programs. Comparable to Bintie's TCR-NK allogeneic strategy on the off-the-shelf cell therapy angle, though using CAR rather than TCR constructs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bintie Biotechnology